Strimvelis Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to advancements in stem cell modification techniques, early success of ada-scid gene therapy trials, increasing regulatory support for orphan drugs, rising awareness of rare immunodeficiency disorders, establishment of centralized treatment centers.

The growth in the forecast period can be attributed to expansion of gene therapy commercialization, increasing investments in rare disease pipelines, growing adoption of personalized medicine approaches, advancements in vector design technologies, rising global access to advanced gene therapies. Major trends in the forecast period include increasing adoption of ex vivo gene therapies, rising focus on personalized genetic treatments, growing utilization of autologous stem cell platforms, expansion of rare disease gene therapy programs, enhanced emphasis on long-term immune reconstitution.

The increasing prevalence of rare genetic disorders is expected to drive the growth of the Strimvelis market going forward. Rare genetic disorders are conditions caused by mutations or changes in an individual’s DNA and occur infrequently in the general population. The rising prevalence of these disorders is attributed to advancements in genetic testing, environmental factors, and, in some cases, lifestyle influences that contribute to DNA mutations. Strimvelis, a gene therapy, addresses rare genetic disorders such as adenosine deaminase severe combined immunodeficiency (ADA-SCID) by using the patient’s own modified stem cells to deliver a functional copy of the ADA gene. This restores immune function and offers a potential long-term cure for individuals with this life-threatening condition. For instance, in May 2024, the National Health Service in the UK reported that approximately 17,000 people in England live with sickle cell disease, an inherited blood disorder, with around 250 new cases diagnosed each year. Therefore, the increasing prevalence of rare genetic disorders is driving growth in the Strimvelis market.

The growing adoption of personalized medicine is expected to further propel the Strimvelis market. Personalized medicine tailors healthcare and treatment strategies to the individual characteristics of each patient. Its adoption is rising due to the availability of precision diagnostic tools, a shift toward value-based healthcare, and the demand for more effective, tailored treatments that improve patient outcomes. Strimvelis supports personalized medicine by offering targeted gene therapy for ADA-SCID patients, using their own stem cells to introduce a functional copy of the ADA gene. This provides a customized, potentially curative treatment based on the patient’s unique genetic profile. For instance, in February 2024, the Personalized Medicine Coalition reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022, including seven cancer drugs and three treatments for other conditions. Therefore, the growing adoption of personalized medicine is driving growth in the Strimvelis market.

The rising healthcare expenditure is expected to drive the Strimvelis market further. Healthcare expenditure refers to the total funds spent on healthcare services and products within a given period. Rising expenditure is fueled by an aging population, increasing prevalence of chronic diseases, medical technology advancements, higher pharmaceutical costs, and expanded access to healthcare services. Increased healthcare spending supports therapies like Strimvelis by funding research, development, accessibility, and administration of innovative treatments, ensuring patients with rare diseases receive life-saving care. For instance, in April 2025, the American Medical Association reported that U.S. health spending increased by 7.5% in 2023 to $4.9 trillion, or approximately $14,570 per capita, compared with 4.6% growth in 2022. Therefore, rising healthcare expenditure is driving growth in the Strimvelis market.

Major companies operating in the strimvelis market are Orchard Therapeutics plc.

North America was the largest region in the strimvelis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the strimvelis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the strimvelis market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the strimvelis market by increasing costs related to imported viral vectors, cell processing equipment, cryopreservation systems, and specialized laboratory consumables required for gene therapy manufacturing. Europe and North America are most affected due to dependence on cross-border biotech supply chains and centralized production facilities. These tariffs are increasing treatment delivery costs and operational complexity for therapy providers. However, they are also driving investment in regional manufacturing hubs, localized vector production, and domestic cell therapy infrastructure to improve long-term supply resilience.

The strimvelis market research report is one of a series of new reports that provides strimvelis market statistics, including strimvelis industry global market size, regional shares, competitors with a strimvelis market share, detailed strimvelis market segments, market trends and opportunities, and any further data you may need to thrive in the strimvelis industry. This strimvelis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Strimvelis is a gene therapy developed to treat adenosine deaminase-severe combined immunodeficiency (ADA-SCID). It uses a patient’s own stem cells, which are collected, genetically modified to correct the defective ADA gene, and then reintroduced to restore immune function and treat ADA-SCID.

The primary clinical indications for Strimvelis include its main therapeutic use, patient population, clinical study data, and mechanism of action. Its primary indication is the treatment of severe combined immunodeficiency (SCID) caused by adenosine deaminase (ADA) deficiency. Strimvelis is distributed through hospitals and pharmacies and serves end users including pediatric and adult patients.

The strimvelis market consists of sales of products including libmeldy, zolgensma, luxturna, roctavian, and skysona. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.